Summary
In two studies, the effects of the potentially interacting drugs mirtazapine and carbamazepine on their pharmacokinetics have been investigated. Subjects were treated with carbamazepine combined with placebo for 21 days and subsequently with carbamazepine combined with mirtazapine for another 7 days (Study A) or with mirtazapine combined with placebo for 7 days and subsequently mirtazapine combined with carbamazepine for another 21 days (Study B). Pharmacokinetic results indicate that carbamazepine decreased significantly AUC and Cmax values for mirtazapine and increased values for demethyl-mirtazapine Cmax. Mirtazapine had no effect on carbamazepine pharmacokinetic parameters, but did lower carbamazepine-10, 11-epoxide levels. Mirtazapine did not affect the single dose kinetics or the enzyme inducing properties of carbamazepine. VAMRS alertness scores reflected the somnolence-inducing effects of carbamazepine and mirtazapine and psychometric test results revealed impairment of specific tasks. The combination was safe and routine laboratory testing did not reveal clinically relevant abnormalities. The dose of mirtazapine in patients on carbamazepine may have to be increased for optimal antidepressant efficacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
De Boer T. (1996): The psychopharmacological profile of mirtazapine. J. Clin. Psychiatry, 57 (suppl 4), 19–25.
Sitsen J.M.A., Zivkov M. (1995): Mirtazapine: clinical profile. CNS Drugs, 4, 39–48.
Davis R., Wilde M.I. (1996): Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs, 5, 389–402.
Wheatley D.P., Van Moffaert M., Timmerman L., Kremer C. M. (1998): Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J. Clin. Psychiatry, 59, 306–312.
Holm K.J., Markham A. (1999): Mirtazapine. A review of its use in major depression. Drugs, 57, 607–631.
Dahl M.-L., Voortman G., Alm C., Elwin C.-E., Delbressine L., Vos R., Bogaards J.J.P., Bertilsson L. (1997): In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin. Drug Invest., 13,37–46.
Leinonen E., Lillsunde P., Laukkanen V., Ykitalo P. (1991): Effects of carbamazepine on serum antidepressant concentration in psychiatric patients. J. Clin. Psychopharmacol., 11, 313–318.
Bond A., Lader M. (1974): The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol., 47, 211–8.
Maris F.A., Dingler E., Niehues S. (1999): High performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma. J. Chromatography B, 721, 309–316.
Heinzel G., Woloszczak R., Thomann P. (1993): TOPFIT Version 2.0 Pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuutgart-Jena-New York: Gustav Fischer Verlag.
Wesnes K., Simpson P., Christmas L., Anand R., McClelland G.R. (1989): The effects of moclobemide on cognition. J. Neural Transm., 29, 91–102.
Holland R.L., Wesnes K., Dietrich B. (1994): Single dose human pharmacology of umespirone. Eur. J. Clin. Pharmacol., 46, 461–468.
Steinijans V.W., Hartmann M., Huber R., Radtke H.W. (1991): Lack of pharmacokinetic interaction as an equivalence problem. Int. J. Pharmacol. Ther. Toxicol., 29, 323–328.
McNamara J.O. (1996): Drugs effective in the therapy of the epilepsies. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Goodman Gilman A., (eds). The pharmacological basis of therapeutics. New York: McGrawHill, Chapter 20, p. 461–486.
Eap C.B., Yasui N., Kaneko S., Baumann P., Powell K., Otani K. (1999): Effects of carbamazepine co-administration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther. Drug Monit., 21, 166–170.
Lucas R.A., Gilfillan D.J., Bergstrom R.F. (1998): A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur. J. Clin. Pharmacol., 54, 639–643.
Delbressine L.P.C., Moonen M.E.G., Kaspersen F.M., Wagenaars G.N., Jacobs P.L., Timmer C.J., Paanakker J.E., Van Hal H.J.M., Voortman G. (1998): Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin. Drug Invest., 15, 45–55.
Sitsen J.M.A., Voortman G., Timmer C.J. (2000): Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J. Psychopharmacol., 14, 172–176.
Radhakishun F.S., Van den Bos J, Van der Heijden BCJM, Roes KCB, O’Hanlon J. (2000): Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J. Clin. Psychopharmacol., 20, 531–537.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sitsen, J.M.A., Maris, F.A. & Timmer, C.J. Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet. 26, 109–121 (2001). https://doi.org/10.1007/BF03190384
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190384